annual CFO:
$189.39M+$34.74M(+22.46%)Summary
- As of today (September 17, 2025), PCRX annual cash flow from operations is $189.39 million, with the most recent change of +$34.74 million (+22.46%) on December 31, 2024.
- During the last 3 years, PCRX annual CFO has risen by +$63.67 million (+50.65%).
- PCRX annual CFO is now at all-time high.
Performance
PCRX Cash from operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFO:
$12.01M-$23.45M(-66.12%)Summary
- As of today (September 17, 2025), PCRX quarterly cash flow from operations is $12.01 million, with the most recent change of -$23.45 million (-66.12%) on June 30, 2025.
- Over the past year, PCRX quarterly CFO has dropped by -$41.22 million (-77.44%).
- PCRX quarterly CFO is now -80.08% below its all-time high of $60.29 million, reached on September 30, 2021.
Performance
PCRX quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFO:
$134.52M-$41.22M(-23.46%)Summary
- As of today (September 17, 2025), PCRX TTM cash flow from operations is $134.52 million, with the most recent change of -$41.22 million (-23.46%) on June 30, 2025.
- Over the past year, PCRX TTM CFO has dropped by -$59.84 million (-30.79%).
- PCRX TTM CFO is now -34.01% below its all-time high of $203.84 million, reached on September 30, 2024.
Performance
PCRX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
PCRX Cash from operations Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +22.5% | -77.4% | -30.8% |
3 y3 years | +50.6% | -59.7% | -6.6% |
5 y5 years | +168.6% | +176.9% | +286.1% |
PCRX Cash from operations Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | at high | +50.6% | -77.7% | at low | -34.0% | +6.4% |
5 y | 5-year | at high | +168.6% | -80.1% | +176.9% | -34.0% | +286.1% |
alltime | all time | at high | +374.3% | -80.1% | +159.4% | -34.0% | +294.8% |
PCRX Cash from operations History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Jun 2025 | - | $12.01M(-66.1%) | $134.52M(-23.5%) |
Mar 2025 | - | $35.46M(+7.0%) | $175.75M(-7.2%) |
Dec 2024 | $189.39M(+22.5%) | $33.13M(-38.6%) | $189.39M(-7.1%) |
Sep 2024 | - | $53.92M(+1.3%) | $203.84M(+4.9%) |
Jun 2024 | - | $53.24M(+8.4%) | $194.36M(+5.3%) |
Mar 2024 | - | $49.10M(+3.2%) | $184.62M(+19.4%) |
Dec 2023 | $154.65M(+6.5%) | $47.58M(+7.1%) | $154.65M(+3.7%) |
Sep 2023 | - | $44.44M(+2.2%) | $149.10M(+1.2%) |
Jun 2023 | - | $43.50M(+127.4%) | $147.32M(+10.2%) |
Mar 2023 | - | $19.13M(-54.5%) | $133.63M(-8.0%) |
Dec 2022 | $145.27M(+15.6%) | $42.04M(-1.4%) | $145.27M(+14.9%) |
Sep 2022 | - | $42.65M(+43.1%) | $126.45M(-12.2%) |
Jun 2022 | - | $29.81M(-3.2%) | $144.09M(-0.2%) |
Mar 2022 | - | $30.78M(+32.6%) | $144.41M(+14.9%) |
Dec 2021 | $125.72M(+63.2%) | $23.21M(-61.5%) | $125.72M(-15.7%) |
Sep 2021 | - | $60.29M(+100.1%) | $149.17M(+15.9%) |
Jun 2021 | - | $30.13M(+149.4%) | $128.66M(+55.2%) |
Mar 2021 | - | $12.08M(-74.1%) | $82.91M(+7.6%) |
Dec 2020 | $77.03M(+9.2%) | $46.67M(+17.3%) | $77.03M(+36.9%) |
Sep 2020 | - | $39.78M(-354.6%) | $56.27M(+61.5%) |
Jun 2020 | - | -$15.62M(-351.7%) | $34.84M(-52.4%) |
Mar 2020 | - | $6.21M(-76.0%) | $73.23M(+3.8%) |
Dec 2019 | $70.52M(+44.3%) | $25.90M(+41.1%) | $70.52M(+7.1%) |
Sep 2019 | - | $18.35M(-19.4%) | $65.84M(+2.7%) |
Jun 2019 | - | $22.76M(+550.6%) | $64.11M(+16.4%) |
Mar 2019 | - | $3.50M(-83.5%) | $55.06M(+12.7%) |
Dec 2018 | $48.87M(+174.8%) | $21.22M(+27.6%) | $48.87M(+9.6%) |
Sep 2018 | - | $16.63M(+21.3%) | $44.58M(+77.3%) |
Jun 2018 | - | $13.71M(-609.9%) | $25.14M(+66.6%) |
Mar 2018 | - | -$2.69M(-115.9%) | $15.09M(-15.2%) |
Dec 2017 | $17.79M | $16.93M(-703.0%) | $17.79M(-2.3%) |
Sep 2017 | - | -$2.81M(-176.8%) | $18.20M(-44.3%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Jun 2017 | - | $3.66M(>+9900.0%) | $32.70M(-10.6%) |
Mar 2017 | - | $6000.00(-100.0%) | $36.58M(+9.3%) |
Dec 2016 | $33.45M(+24.9%) | $17.35M(+48.5%) | $33.45M(+0.9%) |
Sep 2016 | - | $11.68M(+54.9%) | $33.14M(+36.5%) |
Jun 2016 | - | $7.54M(-341.6%) | $24.27M(-4.4%) |
Mar 2016 | - | -$3.12M(-118.3%) | $25.38M(-8.6%) |
Dec 2015 | $26.79M(+1.3%) | $17.04M(+504.7%) | $27.76M(+16.3%) |
Sep 2015 | - | $2.82M(-67.4%) | $23.87M(-20.3%) |
Jun 2015 | - | $8.65M(-1269.1%) | $29.96M(-6.1%) |
Mar 2015 | - | -$740.00K(-105.6%) | $31.89M(+20.6%) |
Dec 2014 | $26.44M(-161.8%) | $13.14M(+47.7%) | $26.44M(+277.9%) |
Sep 2014 | - | $8.90M(-15.9%) | $7.00M(-162.0%) |
Jun 2014 | - | $10.58M(-271.0%) | -$11.29M(-68.0%) |
Mar 2014 | - | -$6.19M(-1.7%) | -$35.28M(-17.5%) |
Dec 2013 | -$42.78M(-38.0%) | -$6.30M(-32.9%) | -$42.78M(-24.4%) |
Sep 2013 | - | -$9.38M(-30.0%) | -$56.59M(-3.1%) |
Jun 2013 | - | -$13.41M(-2.0%) | -$58.38M(-10.5%) |
Mar 2013 | - | -$13.69M(-31.9%) | -$65.19M(-5.6%) |
Dec 2012 | -$69.05M(+122.8%) | -$20.10M(+79.9%) | -$69.05M(+22.1%) |
Sep 2012 | - | -$11.18M(-44.7%) | -$56.55M(+5.0%) |
Jun 2012 | - | -$20.23M(+15.3%) | -$53.86M(+20.9%) |
Mar 2012 | - | -$17.55M(+131.0%) | -$44.56M(+43.7%) |
Dec 2011 | -$31.00M(+24.6%) | -$7.60M(-10.6%) | -$31.00M(+6.0%) |
Sep 2011 | - | -$8.49M(-22.2%) | -$29.24M(+5.7%) |
Jun 2011 | - | -$10.92M(+174.0%) | -$27.66M(+9.5%) |
Mar 2011 | - | -$3.99M(-31.7%) | -$25.27M(+1.6%) |
Dec 2010 | -$24.88M(+19.4%) | -$5.84M(-15.5%) | -$24.88M(+30.7%) |
Sep 2010 | - | -$6.91M(-19.0%) | -$19.04M(+57.0%) |
Jun 2010 | - | -$8.53M(+137.2%) | -$12.13M(+237.2%) |
Mar 2010 | - | -$3.60M | -$3.60M |
Dec 2009 | -$20.84M(-28.6%) | - | - |
Dec 2008 | -$29.19M(+117.3%) | - | - |
Dec 2007 | -$13.44M | - | - |
FAQ
- What is Pacira BioSciences, Inc. annual cash flow from operations?
- What is the all time high annual CFO for Pacira BioSciences, Inc.?
- What is Pacira BioSciences, Inc. annual CFO year-on-year change?
- What is Pacira BioSciences, Inc. quarterly cash flow from operations?
- What is the all time high quarterly CFO for Pacira BioSciences, Inc.?
- What is Pacira BioSciences, Inc. quarterly CFO year-on-year change?
- What is Pacira BioSciences, Inc. TTM cash flow from operations?
- What is the all time high TTM CFO for Pacira BioSciences, Inc.?
- What is Pacira BioSciences, Inc. TTM CFO year-on-year change?
What is Pacira BioSciences, Inc. annual cash flow from operations?
The current annual CFO of PCRX is $189.39M
What is the all time high annual CFO for Pacira BioSciences, Inc.?
Pacira BioSciences, Inc. all-time high annual cash flow from operations is $189.39M
What is Pacira BioSciences, Inc. annual CFO year-on-year change?
Over the past year, PCRX annual cash flow from operations has changed by +$34.74M (+22.46%)
What is Pacira BioSciences, Inc. quarterly cash flow from operations?
The current quarterly CFO of PCRX is $12.01M
What is the all time high quarterly CFO for Pacira BioSciences, Inc.?
Pacira BioSciences, Inc. all-time high quarterly cash flow from operations is $60.29M
What is Pacira BioSciences, Inc. quarterly CFO year-on-year change?
Over the past year, PCRX quarterly cash flow from operations has changed by -$41.22M (-77.44%)
What is Pacira BioSciences, Inc. TTM cash flow from operations?
The current TTM CFO of PCRX is $134.52M
What is the all time high TTM CFO for Pacira BioSciences, Inc.?
Pacira BioSciences, Inc. all-time high TTM cash flow from operations is $203.84M
What is Pacira BioSciences, Inc. TTM CFO year-on-year change?
Over the past year, PCRX TTM cash flow from operations has changed by -$59.84M (-30.79%)